反応式
[C:1]([N:5]1[C:17]2[C:16]3[N:15]=[C:14]([S:18][CH3:19])[N:13]=[CH:12][C:11]=3[CH:10]=[CH:9][C:8]=2[C:7]([C:20]([OH:22])=O)=[N:6]1)([CH3:4])([CH3:3])[CH3:2].[O:23]1[CH2:28][CH2:27][CH2:26][CH2:25][CH:24]1[O:29][NH2:30].CN(C(ON1N=NC2C=CC=CC1=2)=[N+](C)C)C.[B-](F)(F)(F)F.CCN(C(C)C)C(C)C.C([O-])(O)=O.[Na+]>CN(C=O)C.O>[C:1]([N:5]1[C:17]2[C:16]3[N:15]=[C:14]([S:18][CH3:19])[N:13]=[CH:12][C:11]=3[CH:10]=[CH:9][C:8]=2[C:7]([C:20]([NH:30][O:29][CH:24]2[CH2:25][CH2:26][CH2:27][CH2:28][O:23]2)=[O:22])=[N:6]1)([CH3:2])([CH3:3])[CH3:4]参加物
8
反応物 5
生成物 1
試薬・触媒・溶媒 2
実験手順
1-tert-butyl-8-(methylsulfanyl)-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid 40 mg (0.112 mmol) was reacted in dry DMF (2 ml) with O-(tetrahydro-2H-pyran-2-yl)hydroxylamine 25 mg (0.21 mmol), TBTU 70 mg (0.21 mmol) and DIPEA 0.110 ml (1.19 mmol) at room temperature for 3 hours. The reaction was worked up with water, saturated NaHCO3 and extracted with ethyl acetate. The organic phase, dried on Na2SO4, filtered and evaporated, was purified on silica with DCM/EtOAc 7/3 to give 23 mg (50%) of 1-tert-butyl-8-(methylsulfanyl)-N-(tetrahydro-2H-pyran-2-yloxy)-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide. LC/MS (m/z): 416.1 [M+H]+, HPLC (254 nm) method 3 Rt 6.94 min.
後処理
- extractionextracted with ethyl acetate
- customThe organic phase, dried on Na2SO4
- filtrationfiltered
- customevaporated
- customwas purified on silica with DCM/EtOAc 7/3
出典と根拠
- ORDレコード
- ord-9fb976c30e2541bd8939abe6bf1a5a41
- 出典データセット
- uspto-grants-2013_09
- 特許番号
- US08541576B2
関連ノート
読み込み中…